If albuminuria persists despite maximally tolerated RAAS blockade and SGLT2 inhibition, consider adding a non-steroidal MRA. Consider a GLP-1 receptor agonist in patients with obesity or high cardiovascular risk. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.